0.41
-0.0215(-4.95%)
Currency In USD
| Previous Close | 0.43 |
| Open | 0.44 |
| Day High | 0.45 |
| Day Low | 0.41 |
| 52-Week High | 3.39 |
| 52-Week Low | 0.38 |
| Volume | 1.13M |
| Average Volume | 6.14M |
| Market Cap | 16.98M |
| PE | -0.14 |
| EPS | -3.04 |
| Moving Average 50 Days | 1.1 |
| Moving Average 200 Days | 1.5 |
| Change | -0.02 |
If you invested $1000 in Outlook Therapeutics, Inc. (OTLK) since IPO date, it would be worth $0.6 as of February 21, 2026 at a share price of $0.413. Whereas If you bought $1000 worth of Outlook Therapeutics, Inc. (OTLK) shares 5 years ago, it would be worth $8.75 as of February 21, 2026 at a share price of $0.413.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland
GlobeNewswire Inc.
Feb 19, 2026 2:00 PM GMT
Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partnerMediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™ (bevacizumab gamma) in SwitzerlandPartnership adv
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
GlobeNewswire Inc.
Feb 11, 2026 1:45 PM GMT
ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has submi
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
GlobeNewswire Inc.
Jan 06, 2026 1:35 PM GMT
ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed